NCT06081959View on ClinicalTrials.gov

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2027

Conditions
Metastatic Breast Cancer
Interventions
DRUG

SKB264

IV infusion on day 1 and Day 15 of each 28 day cycle

DRUG

Eribulin

1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle

DRUG

Capecitabine

1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle

DRUG

Gemcitabine

1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle

DRUG

Vinorelbine

25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle

Trial Locations (1)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Science, Beijing

All Listed Sponsors
lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY